- Home
- IFS vs ACAD Comparison
IFS vs ACAD Comparison
Compare IFS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFS
- ACAD
- Stock Information
- Founded
- IFS 1897
- ACAD 1993
- Country
- IFS Peru
- ACAD United States
- Employees
- IFS N/A
- ACAD N/A
- Industry
- IFS Commercial Banks
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- IFS Finance
- ACAD Health Care
- Exchange
- IFS Nasdaq
- ACAD Nasdaq
- Market Cap
- IFS 4.2B
- ACAD 3.5B
- IPO Year
- IFS 2019
- ACAD 2004
- Fundamental
- Price
- IFS $36.34
- ACAD $22.63
- Analyst Decision
- IFS Buy
- ACAD Buy
- Analyst Count
- IFS 1
- ACAD 18
- Target Price
- IFS $30.00
- ACAD $27.94
- AVG Volume (30 Days)
- IFS 163.9K
- ACAD 1.6M
- Earning Date
- IFS 08-11-2025
- ACAD 08-06-2025
- Dividend Yield
- IFS 2.61%
- ACAD N/A
- EPS Growth
- IFS 70.43
- ACAD N/A
- EPS
- IFS 3.84
- ACAD 1.37
- Revenue
- IFS $1,334,218,842.00
- ACAD $996,283,000.00
- Revenue This Year
- IFS N/A
- ACAD $13.28
- Revenue Next Year
- IFS $8.71
- ACAD $11.06
- P/E Ratio
- IFS $9.48
- ACAD $16.62
- Revenue Growth
- IFS 25.66
- ACAD 22.42
- 52 Week Low
- IFS $21.40
- ACAD $13.40
- 52 Week High
- IFS $38.65
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- IFS 47.27
- ACAD 55.57
- Support Level
- IFS $35.65
- ACAD $22.09
- Resistance Level
- IFS $37.15
- ACAD $23.60
- Average True Range (ATR)
- IFS 0.71
- ACAD 0.75
- MACD
- IFS -0.18
- ACAD 0.03
- Stochastic Oscillator
- IFS 31.94
- ACAD 64.47
About IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.